Vomiting in Infants and/or Children clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 30 months to 18 years
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving hematopoietic stem cell transplant (HSCT) conditioning experience CINV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving chemotherapy for HSCT conditioning.
San Francisco, California and other locations
Our lead scientists for Vomiting in Infants and/or Children research studies include Christopher Dvorak.